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Abstract
Background: A large amount of information has been collected on the molecular tumorigenesis of thyroid cancer.
A low expression of c-KIT gene has been reported during the transformation of normal thyroid epithelium to
papillary carcinoma suggesting a possible role of the gene in the differentiation of thyroid tissue rather than in the
proliferation. The initial presentation of thyroid carcinoma is through a nodule and the best way nowadays to
evaluate it is by fine-needle aspiration (FNA). However many thyroid FNAs are not definitively benign or malignant,
yielding an indeterminate or suspicious diagnosis which ranges from 10 to 25% of FNAs. BRAF mutational analysis
is commonly used to assess the malignancy of thyroid nodules but unfortunately it still leaves indeterminate
diagnoses. The development of molecular initial diagnostic tests for evaluating a thyroid nodule is needed in order
to define optimal surgical approach for patients with uncertain diagnosis pre- and intra-operatively.
Methods: In this study we extracted RNA from 82 FNA smears, 46 malignant and 36 benign at the histology, in
order to evaluate by quantitative Real Time PCR the expression levels of c-KIT gene.
Results: We have found a highly preferential decrease rather than increase in transcript of c-KIT in malignant
thyroid lesions compared to the benign ones. To explore the diagnostic utility of c-KIT expression in thyroid
nodules, its expression values were divided in four arbitrarily defined classes, with class I characterized by the
complete silencing of the gene. Class I and IV represented the two most informative groups, with 100% of the
samples found malignant or benign respectively. The molecular analysis was proven by ROC (receiver operating
characteristic) analysis to be highly specific and sensitive improving the cytological diagnostic accuracy of 15%.
Conclusion: We propose the use of BRAF test (after uncertain cytological diagnosis) to assess the malignancy of
thyroid nodules at first, then the use of the c-KIT expression to ultimately assess the diagnosis of the nodules that
otherwise would remain suspicious. The c-KIT expression-based classification is highly accurate and may provide a
tool to overcome the difficulties in today’s preoperative diagnosis of thyroid suspicious malignancies.
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Introduction
Thyroid carcinoma represents 90% of all endocrine
malignancies and about 1% of all human malignancies,
with an increasing incidence [1]. Papillary thyroid carci-
noma (PTC) is its most frequent histotype and usually its
first clinical presentation is a thyroid nodule [2,3]. Five to
10% of the population will develop a clinically significant
thyroid nodule during their lifetime [4], whereas PTC
accounts only for 5% of all thyroid nodules [5].
A large amount of information has been accumulated
on the molecular pathogenesis of thyroid cancer [6]. For
what concerns PTC, the activation of MAPK signalling
pathway is a major event, as a result either of BRAF or
RAS point mutations or RET/PTC rearrangement.
The proto-oncogene c-KIT is a type III receptor tyro-
sine-kinase, cellular homolog of the viral oncogene of
the feline sarcoma retrovirus HZ4-FeSV. It plays various
roles in haematopoiesis, melanogenesis and spermato-
genesis, and in the development of the interstitial cells
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cleared yet. A number of tumour types are associated
with activation of c-KIT through its overexpression or
through activating mutations [7,9-11], while in highly
metastatic melanomas, breast cancer and thyroid carci-
noma the progression into a malignant phenotype corre-
lates mostly with loss of c-KIT expression [12-16].
Among the few papers studying c-KIT status in thyroid
cancer, Natali et al. in 1995 [17] reported the loss of the
receptor during the transformation of normal thyroid
epithelium to papillary carcinoma. Similarly, in 2004
Mazzanti et al. [18], by using a microarray assay, were
able to identify, out of thousands of genes, c-KIT as one
of the most significant down-expressed gene in PTC
compared to benign lesions. Other laboratories con-
firmed this result by using quantitative Real-Time PCR
(qPCR) [19,20]. Moreover, multiple miRNAs, predicted
to target c-KIT, have been reported to be up-regulated
in PTC [21,22]. These findings indicate that the c-KIT
receptor may be involved in the growth control of thyr-
oid epithelium and that this function may be lost in
malignant transformation.
Nowadays, thyroid fine-needle aspiration cytology
(FNAC) is the best available test in the evaluation of a
thyroid nodule [23,24] and has greatly reduced the need
for thyroid surgery. Unfortunately, a percentage of FNAC
(~ 30%) is suspicious for papillary carcinoma (SPTC) or
reveals an indeterminate follicular proliferation (IFP), not
allowing a sure diagnosis of malignity or benignity [25-28].
According to the Guidelines for the Management of Thyr-
oid Cancer, British Thyroid Association, SPCT corre-
sponds to the abbreviation Thy4 and IFP to Thy3.
As in other diseases, molecular pathology is playing a
relevant role in diagnosis of thyroid cancer. Recently, sev-
eral studies have demonstrated that the BRAF V600E
mutation represents a diagnostic and prognostic biomar-
ker in PTC, with a prevalence of 40-66%, whereas it is
never found in benign lesion [29,30]. Very recent papers
of our laboratory have proposed a new simple method,
named manual macrodissection, to perform molecular
analysis on cells obtained by FNAC, and have demon-
strated the usefulness of the association cytology-molecu-
lar biology for PTC and micro-PTC diagnosis. In
particular, the analysis of the BRAF gene status increases
the diagnostic accuracy for PTC of 20-30%. However
BRAF V600E analysis still leaves a percentage of SPTC
and IFP, urging the finding of other molecular markers.
The present study evaluates c-KIT expression in a mor-
pho-molecular diagnostic approach to a series of thyroid
FNAC, together with the study of BRAF gene status. We
confirm the down regulation of c-KIT in PTC, and show




Preoperative FNAC slides of 82 thyroid nodules from as
many patients were selected from files of the Section of
Cytopathology, Division of Surgical, Molecular and
Ultrastructural Pathology, University of Pisa, collected
from 2003 to 2010. For ethical reasons, only cases with
extra slides were used. Selected cells (neoplastic, SPTC
or IFP) were manually scraped with a method previously
described, named manual macrodissection [29].
Ethical Board
This study was approved by the Internal Review Board
of the University of Pisa. All patients gave their consent
for the participation to the study.
Diagnosis
Cytological diagnosis was based on the following criteria,
broadly suggested in the literature: smear background, cell
arrangements, cell shape, nuclear/cytoplasmic features,
presence of nucleoli and mitosis. In particular, the cytolo-
gical diagnosis of IFP was based on the presence of micro-
follicular pattern, irregularity of structure and absence of
colloid, whereas nuclear atypia and mitosis were not pre-
sent. Histological diagnosis assessed ultimately the malig-
nity or benignity of all lesions.
Smears were independently reviewed by senior cyto-
pathologists to assure adequate thyroid cell representation
of the slides in which molecular analysis was performed.
The histological diagnosis of the 82 samples collected
was of PTC in 46 cases and of benign nodule in 36 cases.
As described in Table 1, of the 46 cases with a definitive
histological diagnosis of PTC, the cytological diagnosis
was of PTC in 30 cases (65%), of SPTC in 11 cases (24%)
and of IFP in 5 cases (11%). In the 36 cases with a defini-
tive histological diagnosis of benign nodule, the cytological
diagnosis was of benign nodule (BN) in 17 cases (47%)
and of IFP in 19 cases (53%).
DNA and RNA extraction
Archival FNAC slides stained with Papanicolaou techni-
que were kept in xylene for 1 to 3 days, depending on the
time of storage, in order to detach the slides coverslips.
Table 1 Histological and cytological diagnoses of 82
thyroid nodules
Histological Diagnosis Cytological Diagnosis
PTC SPTC IFP
PTC: 46 cases 30 (65%) 11 (24%) 5 (11%)
BN IFP
BN: 36 cases 17 (47%) 19 (53%)
PTC: papillary thyroid carcinoma. SPTC: suspicious for PTC. IFP: indeterminate
follicular proliferation. BN: benign nodule.
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baths, followed by a wash in distilled H2Of o r1m i n u t e
and finally air-dried. DNA extraction was performed using
a commercially available kit (Nucleospin, Macherey-Nagel,
Düren, Germany) with a modification to the first step.
Fifty percent of the lysis solution without proteinase K was
initially poured on the slide to scrape off the cytological
stained sample using a single edged razor blade. Any
scraped tissue was then collected in a microcentrifuge
tube containing the other half of the lysis solution with
Proteinase K. The extracted DNA was kept at -20° until
used. RNA extraction was performed by using a commer-
cial kit (High Pure RNA Paraffin kit, Roche). The quan-
tity/quality of extracted RNA and DNA was estimated
with Nanodrop 1000 spectrophotometer by using 1 μlo f
undiluted RNA/DNA solution. RNA was then reverse
transcribed in cDNA in a final volume of 20 μl, containing
5X RT buffer, 10 mM dNTPs, 50 ng/μl Random Primers,
0.1 M DTT, 40 U/μlR N a s e O U T ,5 0μMo l i g o ( d T ) ,D E P C -
Treated Water, 15 U/μl Cloned AMV reverse transcriptase
(Invitrogen, Carlsbad, CA).
c-KIT mRNA expression analysis
The level of c-KIT expression was analysed by quantitative
Real-Time PCR (qPCR) on the Rotor-Gene 6000 real time
rotary analyzer (Corbett, Life Science, Australia) following
the manufacturing instructions. Endogenous reference
gene (B2M, beta 2 microglobulin) was used to normalize
each gene expression level. PCR was performed in 25 μl
final volume, containing 5 μlo fc D N A ,1 2 . 5μlo fM E S A
GREEN qPCR MasterMix Plus (EUROGENTEC, San
Diego, CA), 300 nM of each primer (Invitrogen, Carlsbad,
CA) with the following cycling conditions: initial denatura-
tion 95°C for 5 min; 40 cycles at 95°C for 15 sec and 58°C
for 40 sec and 72°C for 40 sec; final step 25°C for 1 min.
Primers for c-KIT and B2M amplification were selected
using Primer3 software:
- c-KIT F: 5’- GCACCTGCTGCTGAAATGTATGA-
CATAAT-3’
-c - K I TR :5 ’- TTTGCTAAGTTGGAGTAAATAT-
GATTGG-3’
- B2M F: 5’- CATTCCTGAAGCTGACAGCATTC-3’
- B2M R: 5’- TGCTGGATGACGTGAGTAAACC-3’
A first PCR run was performed on control c-KIT expres-
sing sample and run on 2% agarose gel. The PCR product
was excised from the gel, purified by using GenElute™
PCR Clean-Up (Sigma-Aldrich) and measured spectropho-
tometrically at 260 and 280 nm.
The purified product was diluted in a 10-fold series to
create the standards for a ten-point standard curve that
was run in triplicate. Standard curves were generated for
both c-KIT and B2M and showed a good linearity with
consistent correlation coefficient (R
2 = 0.999). Ct was
determined by the Rotor-Gene 6000 software and
exported for analysis after background subtraction.
T h r e s h o l dw a ss e tb ys t a n d a r dc u r v ea n dt h e ni m p o r t e d
in all the runs for data analysis. PCR efficiencies resulted
similar for both c-KIT and B2M in each experiment and
ranged between 98-102%. The experiment was run in
duplicate for each sample.
To verify primers specificities, melting curve analysis
was performed. Fluorescent data were acquired during the
extension phase. After 40 cycles a melting curve for each
gene was generated by slowly increasing (0.1°C/s) the tem-
perature from 60°C to 95°C, while the fluorescence was
measured. For each experiment a no-template reaction
was included as a negative control.
c-KIT expression was ultimately represented as the ratio
of absolute quantification by standard curve of c-KIT
expression and B2M expression.
c-KIT genotyping
c-KIT sequence was screened for mutations in exons 9, 11,
13 and 17 by direct sequencing. PCR was performed using
standard conditions: initial denaturation 95°C for 7 min;
40 cycles at 95°C for 45 sec and 56°C for 45 sec and 72°C
for 45 sec; final step 72°C for 10 min with AmpliTaq Gold
(Applied Biosystems) on 9700 GeneAmp PCR System
(Applied Biosystems). Primers for c-KIT sequencing were
selected using Primer3 software:
- exon 9 F: 5’- CCAGGGCTTTTGTTTTCTTC-3’
- exon 9 R: 5’- TGGTAGACAGAGCCTAAACATCC-3’
- exon 11 F: 5’- GATCTATTTTTCCCTTTCTC-3’
- exon 11 R: 5’- AGCCCCTGTTTCATACTGAC-3’
- exon 13 F: 5’- TCAGTTTGCCAGTTGTGCTT-3’
- exon 13 R: 5’- AATGTCATGTTTTGATAACCT-3’
- exon 17 F: 5’- TTCTTTTCTCCTCCAACCTAA-3’
- exon 17 R: 5’- TGTCAAGCAGAGAATGGGTA-3’
The PCR products were purified with Multi Screen PCR
Plates (Millipore) and the sequencing reactions were per-
formed in 20 μl final volume using Big Dye Terminator kit
v3.1 (Applied Biosystems) and 2.5 pmol/μlo fe a c hp r i m e r ,
then purified with Multi Screen PCR Plates (Millipore).
The sequence reactions were loaded on ABI PRISM 3100
Genetic Analyzer (Applied Biosystems) and analyzed using
the Sequencing Analysis software 3.4 version.
BRAF V600E mutational status
The BRAF V600E mutational status was determined by
automated pyrosequencing analysis (Qiagen).
Statistical analysis
Student’s t-test was used to compare the mean of c-KIT
expression between malignant and benign samples. Chi-
square test was used to statistically analyse each single
class of c-KIT versus the sum of the other ones. Then
malignity and benignity indexes, which represent the per-
centage of cases with a malignant or benign diagnosis in
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reported. To better estimate the significance of the malig-
nity index trend we also performed a logistic regression.
All the analyses were performed by using Statgraphics
Centurion (V. 15, StatPoint, Inc.). In order to evaluate
t h eA r e aU n d e rt h eC u r v e( A U C )a sam e a s u r eo fs e n s i -
tivity and specificity of our method, we used a ROC
(receiver operating characteristic) curve analysis (Med-
calc 11, Medcalc Software). To evaluate the statistical sig-
nificance of the change in diagnostic accuracy before and
after performing molecular analyses we used Chi-square
test for comparison of two proportions (independent
samples) expressed as a percentage.
Results
Expression and genotyping of c-KIT receptor in benign
and malignant thyroid lesions
c-KIT expression was analyzed by qPCR in a set of 82
FNAC, histologically diagnosed as 36 benign and 46
malignant thyroid nodules (Table 2). Overall, c-KIT
expression was detected in 59% of PTC (27/46) and in
100% of BN (36/36). The mean of c-KIT expression
values (c-KIT/B2M ratio) was calculated for both benign
(1.72) and malignant (0.138) groups and the difference
resulted highly significant (p < 0.0001).
The sequencing of exons 9, 11, 13, 17 of the c-KIT
resulted wild-type for all the samples analyzed.
c-KIT expression and biological behavior of thyroid
nodules
The value of c-KIT expression (c-KIT/B2M ratio) ranged
between 0 and 9.34 (Table 2). To evaluate a possible rela-
tionship with the biological behavior of lesions, c-KIT
expression values (ev) were arbitrarily organized in four
classes (Table 3):
- Class I: c-KIT ev = 0;
- Class II: c-KIT ev > 0 and ≤ 0.5;
- Class III: c-KIT ev > 0.5 and ≤ 3;
- Class IV: c-KIT ev > 3;
The percentage of malignant and of benign cases was
calculated in each class and its statistical significance
was determined (p-value).
In class I the percentage of malignancy is 100% (19/19
cases), whereas in class IV the percentage of benignity is
100% (5/5). In class II the percentage of malignant cases
is higher than benign cases: 65% (24/37) vs 35% (13/37).
On the other hand, class III has a higher percentage of
benign cases than malignant ones: 86% (18/21) vs 14%
(3/21). Difference between malignant and benign lesions
is statistically highly significant in classes I, IV and III
(p < 0.0001, p = 0.0091, p < 0.0001). p-value in class II
is 0.14.
Figure 1 reports the results of fitting a logistic regres-
sion model. The p-value of the diagnostic model is less
Table 2 Morphological and molecular diagnosis in 82
thyroid nodules
case HD CD c-KIT Class c-KIT ev BRAF
1 PTC PTC I 0 V600E
2 PTC PTC I 0 V600E
3 PTC PTC I 0 V600E
4 PTC PTC I 0 V600E
5 PTC PTC I 0 V600E
6 PTC PTC I 0 V600E
7 PTC PTC I 0 V600E
8 PTC PTC I 0 V600E
9 PTC PTC I 0 V600E
10 PTC PTC I 0 V600E
11 PTC PTC I 0 V600E
12 PTC PTC I 0 V600E
13 PTC PTC I 0 WT
14 PTC PTC I 0 WT
15 PTC PTC I 0 WT
16 PTC PTC II 0.5 V600E
17 PTC PTC II 0.448 V600E
18 PTC PTC II 0.105 V600E
19 PTC PTC II 0.07 V600E
20 PTC PTC II 0.0533 V600E
21 PTC PTC II 0.049 V600E
22 PTC PTC II 0.031 V600E
23 PTC PTC II 0.022 WT
24 PTC PTC II 0.013 V600E
25 PTC PTC II 0.0126 WT
26 PTC PTC II 0.01 WT
27 PTC PTC II 0.004 WT
28 PTC PTC II 0.0003 WT
29 PTC PTC II 0.0002 V600E
30 PTC PTC III 1.0506 WT
31 PTC SPTC I 0 WT
32 PTC SPTC I 0 WT
33 PTC SPTC I 0 WT
34 PTC SPTC I 0 WT
35 PTC SPTC II 0.44 V600E
36 PTC SPTC II 0.42 V600E
37 PTC SPTC II 0.022 V600E
38 PTC SPTC II 0.011 V600E
39 PTC SPTC II 0.42 WT
40 PTC SPTC II 0.37 WT
41 PTC SPTC III 1.27 WT
42 PTC IFP II 0.275 WT
43 PTC IFP II 0.097 WT
44 PTC IFP II 0.07 WT
45 PTC IFP II 0.023 WT
46 PTC IFP III 0.57 WT
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between the variables at the 95% confidence level. Speci-
ficity and sensitivity of the diagnostic performance of
the model were evaluated by ROC analysis and the
AUC was 0.881, with C.I. 95% 0.79-0.94 and p = 0.001,
indicating that the model has a statistically significant
efficacy in discriminating malignant from benign lesions
(Figure 2).
c-KIT expression in FNAC
The cytological diagnoses of the 46 histologically con-
firmed PTCs were distributed through the 4 classes as
following (Table 4):
- 30 cases cytologically diagnosed as PTC: 15 (50%)
were in class I, 14 (47%) in class II, 1 (3%) in class III
and none (0%) in class IV.
- 11 cases cytologically diagnosed as SPTC: 4 (36%) in
class I, 6 (55%) in class II, 1 (9%) in class III and none
(0%) in class 4.
- 5 cases cytologically diagnosed as IFP: 4 (80%) were
in class II, 1 (20%) in class III, whereas no case was pre-
sent in class I and IV.
The cytological diagnoses of the 36 histologically con-
firmed BN were distributed through the 4 classes as
following:
- 17 cases cytologically diagnosed as benign: 5 (29%)
were in class II, 11 (65%) in class III, 1 (6%) in class IV,
whereas no case was present in class I.
- 19 cases cytologically diagnosed as IFP: 8 (42%) were
in class II, 7 (37%) in class III and 4 (21%) in class IV,
whereas no case was present in class I.
Table 2 Morphological and molecular diagnosis in 82
thyroid nodules (Continued)
47 BN BN II 0.3 WT
48 BN BN II 0.14 WT
49 BN BN II 0.07 WT
50 BN BN II 0.1079 WT
51 BN BN II 0.363 WT
52 BN BN III 0.561 WT
53 BN BN III 0.6457 WT
54 BN BN III 0.858 WT
55 BN BN III 0.96 WT
56 BN BN III 0.97 WT
57 BN BN III 1.051 WT
58 BN BN III 1.3823 WT
59 BN BN III 1.39 WT
60 BN BN III 2.47 WT
61 BN BN III 2.5083 WT
62 BN BN III 2.6333 WT
63 BN BN IV 7.24 WT
64 BN IFP II 0.032 WT
65 BN IFP II 0.04 WT
66 BN IFP II 0.0463 WT
67 BN IFP II 0.0599 WT
68 BN IFP II 0.1143 WT
69 BN IFP II 0.1957 WT
70 BN IFP II 0.217 WT
71 BN IFP II 0.2619 WT
72 BN IFP III 0.7302 WT
73 BN IFP III 0.84 WT
74 BN IFP III 0.948 WT
75 BN IFP III 1.09 WT
76 BN IFP III 1.3727 WT
77 BN IFP III 1.64 WT
78 BN IFP III 1.67 WT
79 BN IFP IV 3.4 WT
80 BN IFP IV 7.69 WT
81 BN IFP IV 8.73 WT
82 BN IFP IV 9.34 WT
HD: histological diagnosis. CD: cytological diagnosis. c-KIT ev: c-KIT expression
value. PTC: papillary thyroid carcinoma. SPTC: suspicious for PTC. BN: benign
nodule. IFP: indeterminate follicular proliferation. WT: wild type.
Table 3 Classes of c-KIT expression value
Class c-KIT ev PTC BN p value
n%n%
I 0 19 100 0 0 < 0.0001
II > 0-≤ 0.5 24 65 13 35 = 0.1400
III > 0.5-≤ 3.0 3 14 18 86 < 0.0001
IV > 3 0 0 5 100 = 0.0091
46 36
c-KIT ev: c-KIT expression value. PTC: papillary thyroid carcinoma. BN: benign
nodule.
Figure 1 Logistic regression. Logistic regression model describing
the relationship between the risk of malignancy and the classes of c-
KIT expression. The p-value of the model resulted to be less than 0.05.
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cytological samples
The BRAF V600E mutation (Table 2) was found in 54%
of the 46 malignant samples (25/46). 48% BRAF V600E
mutated samples were in c-KIT class I (12/25), as
shown in Table 5. Class II contained the residual 52% of
BRAF mutated cases (13/25). Class III and IV had no
BRAF mutated cases. BRAF V600E was significantly
more present in class I and II (p = 0.00026). No benign
samples were BRAF mutated.
c-KIT/BRAF combined molecular analysis in thyroid
nodule FNAC
Table 5 shows that four cases of SPTC are in c-KIT
class I, whereas four more cases harbor a BRAF V600E
mutation. All these 8 cases can be reasonably considered
a sP T C .A tt h es a m et i m e ,t h ef o u rc a s e sw i t hac y t o l o -
gical diagnosis of IFP that are in c-KIT class IV can rea-
sonably considered as benign nodules.
Role of molecular diagnosis in increasing the diagnostic
accuracy of FNAC
As shown in Table 6, if the 8 cases of SPTC in c-KIT
class I or hosting a BRAF V600E mutation are moved to
the diagnostic group of PTC, the total number of PTC
rises from 30 (65%) to 38 (83%), with an advantage in
diagnostic accuracy of malignancy of 18%.
On the other hand, if the 4 cases of IFP in c-KIT class
IV are moved to the diagnostic group of BN, the total
number of BN rises from 17 (47%) to 21 (58%), with an
advantage in diagnostic accuracy of benignity of 11%.
Finally, if we consider both PTC diagnosis and BN
diagnosis, the whole diagnostic accuracy gain is of 15%
with a statistically significant p-value of 0.03.
Discussion
Papillary thyroid carcinoma (PTC) is the most common
malignancy in thyroid tissue; about 80% of incident
thyroid cancers are PTC. Although PTC is usually asso-
ciated with alterations in the RET/PTC-RAS-BRAF sig-
naling pathway [31,32], the detailed molecular
mechanism is unclear. A few papers mentioning a role
for c-KIT in thyroid malignancies suggested to perform
an analysis of c-KIT expression on thyroid cells obtained
by FNAC from benign and malignant thyroid nodules,
with the double aim to study a human model of thyroid
cancer and, at the same time, to verify if c-KIT expres-
sion analysis could be of any clinical interest. The pre-
sent study evaluated c-KITe x p r e s s i o ni nag r o u po f
thyroid FNAC, assessed later on as malignant or benign
by post-surgical histological analysis, and describes the
silencing of c-KIT in PTC. These data are in full accor-
dance with a previous paper of Mazzanti et al. [18], who
were able to identify two classifier models, of 10 and 6
genes respectively, discriminative of PTC and BN, in
Table 4 Distribution of cytological diagnosis in the c-KIT expression classes
HD CD class I class II class III class IV
n%n%n %n %
PTC PTC: 30 15 50 14 47 1 3 0 0
SPTC: 11 4 36 6 55 1 9 0 0
IFP: 5 0 0 4 80 1 20 0 0
total 46 19 24 3 0
BN BN: 17 0 0 5 29 11 65 1 6
IFP: 19 0 0 8 42 7 37 4 21
total 36 13 18 5
HD: histological diagnosis. CD: cytological diagnosis. PTC: papillary thyroid carcinoma. SPTC: suspicious for PTC. IFP: indeterminate follicular proliferation. BN:
benign nodule. n: number of cases.
Figure 2 ROC analysis for c-KIT expression. The true positive rate
(Sensitivity) is plotted in function of the false positive rate (100-
Specificity) for different cut-off points. Each point on the ROC plot
represents a sensitivity/specificity pair corresponding to a particular
decision threshold. (AUC = 0.9, C.I 95% 0.79-.94; p = 0.001).
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c-KIT resulted heterogeneously expressed in goiters,
whereas PTC were negative. These data give also
strength to the report that multiple miRNAs predicted
to target c-KIT (miR-221, miR-222, miR-146) are up-
regulated in PTC [21,22].
The biological significance of loss of c-KIT in thyroid
malignancies is not clear. SCF, the c-KIT ligand, is not
mitogenic in primary cultures of thyrocytes even in con-
junction with thyroid-stimulating hormone [33], a result
which would indicate that SCF/c-KIT pathway may con-
trol some aspects of the thyrocyte differentiated pheno-
type rather than cell division. This would agree with the
apparently strong selection for loss of c-KIT expression
in neoplastic transformation of thyroid epithelium. This
negative selection is in stark contrast with the gain of
function due to genetic alterations of tyrosine kinase
receptors (TRKs) in other types of cancers, suggesting
that TRK signaling pathways may have opposite biologi-
cal effects in different cell types.
To explore the diagnostic utility of c-KIT expression in
thyroid nodules, its expression values were divided in
four arbitrarily defined classes, with class I characterized
by the complete silencing of the gene. Class I and IV
represented the two most informative groups, with 100%
of the samples found malignant or benign respectively.
Class III was also very informative including 86% of
benign samples and having over all the highest statistical
significance. On the other hand, in class II the samples
belonging to the malignant group were 66%, which
resulted non significant. A ROC analysis was performed
to measure the diagnostic performance of the model
(Figure 2), showing its good efficacy in predicting the
malignant events (AUC = 0.9 C.I 95% 0.79-.94; p =
0.001). However, we did not test c-KIT model on
unknown samples, since cytological smears employed in
this study were obtained from nodules whose histological
diagnosis was known. Thus, additional blind samples are
required to strengthen the utility of c-KIT test in the pre-
operative diagnosis.
Moreover, quite interestingly, BRAF V600E mutation,
which is a well-known marker for PTC, was found to be
statistically more present in the c-KIT classes I and II,
while class III and IV did not contain any sample, sup-
porting therefore the association of low c-KIT expres-
sion levels to a malignant status.
Molecular Pathology is the modern version of Pathol-
ogy, where the whole of morphology and molecular
alterations represents a powerful approach to diagnosis.
In this line, this study aimed to verify the diagnostic
potential of c-KIT expression analysis and demonstrated
that the combined BRAF mutation and c-KIT expres-
sion approach is able to increase the diagnostic accuracy
of FNAC of thyroid nodules of 18% for a diagnosis of
malignancy and 11% for a diagnosis of benignity.
Despite several carcinomas showed activating muta-
tions of c-KIT gene (GISTs, melanomas, haematopoietic
and lymphoid tumors), they have not been described in
thyroid tumors and this study revealed a wild type
sequence of c-KIT gene in exons 9, 11, 13, and 17.
Finally, as previously published by Jin et al. [34], the
present paper shows that not only DNA but RNA too
can be easily extracted from stained smears of FNAC and
easily analyzed by qPCR. c-KIT receptor expression was
detectable regardless of the time of specimen collection
from the archived material, we were able to successfully
use slides prepared 7 years ago and kept in our archives.
Moreover all of the smears were independently reviewed
by a senior cytopathologist before assessing c-KIT
expression, to assure adequate thyroid cell representation
of the slides in which c-KIT receptor expression was
Table 5 BRAF mutational status according to c-KIT expression classes and to morphological diagnosis
HD CD class I class II class III class IV
V600E WT V600E WT V600E WT V600E WT
PTC: 46 PTC: 30 12 3 9 50100
SPTC: 11 0 4 4 20100
IFP: 5 0 0040100
B N : 3 6 B N : 1 700050 1 1 01
IFP: 19 0 0080704
HD: histological diagnosis. CD: cytological diagnosis. WT: wild type. PTC: papillary thyroid carcinoma. SPTC: suspicious for PTC. IFP: indeterminate follicular
proliferation.
Table 6 Role of molecular diagnosis in increasing the
diagnostic accuracy of FNAC




PTC 30/46: 65% 38/46: 83% + 18%
BN 17/36: 47% 21/36: 58% + 11%
PTC + BN 47/82: 57% 59/82: 72% + 15%
CD: cytological diagnosis. PTC: papillary thyroid carcinoma. SPTC: suspicious
for PTC. BN: benign nodule. MD: molecular diagnosis. DA: diagnostic accuracy.
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Page 7 of 9investigated. The simple method named manual macro-
dissection and described elsewhere allows to perform
molecular analysis only on selected cell population to be
studied. This specialized test that may have increased uti-
lity as testing based on RNA is becoming more wide-
spread and easily available.
Conclusion
In summary, we have demonstrated that c-KIT expres-
sion-based classification of thyroid lesions is highly
accurate and may provide a tool to overcome the diffi-
culties in today’s preoperative diagnosis of thyroid suspi-
cious malignancies. We hoped that the test proposed in
this paper will be a useful adjunct to the preoperative
diagnosis of thyroid nodules.
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